pSivida's Partner Alimera Sciences Announces an Agreement to Raise Capital to Fund the Development and Commercialization of ILUVIEN®
"We are very pleased that Alimera has announced its intention to proceed
with the direct commercialization of ILUVIEN in the
Alimera reported that the closing of its proposed financing is subject
to customary closing conditions, including the approval of the holders
of a majority of the outstanding shares of common stock of Alimera, as
required under the applicable regulations of The
About
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. These include
statements regarding Alimera completing its proposed financing, the
allocation of net proceeds by Alimera to the development and
commercialization of ILUVIEN, and the potential for and timing of French
and German market authorization of ILUVIEN. The following are some of
the factors that could cause actual results to differ materially from
the anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements: conditions to the Alimera
capital raise may not be satisfied, if the Alimera's proposed offering
closes, Alimera may fail to deploy substantial net proceeds to the
commercialization of ILUVIEN; the timing and conditions for additional
regulatory approvals are subject to decisions by regulators; necessity
to raise additional capital to finance Phase III uveitis trials as well
as other working capital needs; ability to obtain additional capital;
ability to initiate and complete clinical trials and obtain regulatory
approval of product candidates; adverse side effects; Alimera's ability
to successfully obtain regulatory approval of and commercialize ILUVIEN
for DME in the EU; actions with respect to regulatory approval of
ILUVIEN for DME in the U.S.; ability to attain profitability; exercise
by Pfizer of the Latanoprost Product option; further impairment of
intangible assets; fluctuations in operating results; decline in royalty
revenues; ability to find partners to develop and market products;
termination of license agreements; competition; market acceptance of
products and product candidates; reduction in use of products as a
result of future guidelines, recommendations or studies; ability to
protect intellectual property and avoid infringement of others'
intellectual property; retention of key personnel; product liability;
consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs
of international business operations; credit and financial market
conditions; legislative or regulatory changes; volatility of stock
price; possible dilution; possible influence by Pfizer; ability to pay
any registration penalties; absence of dividends; and other factors
described in our filings with the
US:
bjedynak@janispr.com
or
brianl@psivida.com
Source:
News Provided by Acquire Media
